S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
New AI Stock Payouts (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
New AI Stock Payouts (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
New AI Stock Payouts (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
New AI Stock Payouts (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
New AI Stock Payouts (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
New AI Stock Payouts (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
New AI Stock Payouts (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
New AI Stock Payouts (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
NASDAQ:KMDA

Kamada (KMDA) Competitors

$5.17
-0.11 (-2.08%)
(As of 09/22/2023 ET)
Compare
Today's Range
$5.17
▼
$5.29
50-Day Range
$4.86
▼
$5.83
52-Week Range
$3.72
▼
$5.85
Volume
5,621 shs
Average Volume
19,070 shs
Market Capitalization
$231.72 million
P/E Ratio
64.63
Dividend Yield
N/A
Price Target
$11.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

KMDA vs. GRCL, SBTX, ATAI, VSTM, IMRX, AKBA, NVCT, SGMT, RPHM, and LFCR

Should you be buying Kamada stock or one of its competitors? The main competitors of Kamada include Gracell Biotechnologies (GRCL), Silverback Therapeutics (SBTX), Atai Life Sciences (ATAI), Verastem (VSTM), Immuneering (IMRX), Akebia Therapeutics (AKBA), Nuvectis Pharma (NVCT), Sagimet Biosciences (SGMT), Reneo Pharmaceuticals (RPHM), and Lifecore Biomedical (LFCR). These companies are all part of the "pharmaceutical preparations" industry.

Kamada vs.

Kamada (NASDAQ:KMDA) and Gracell Biotechnologies (NASDAQ:GRCL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, community ranking, risk, valuation, dividends, earnings and analyst recommendations.

34.1% of Kamada shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 28.0% of Gracell Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Kamada has higher revenue and earnings than Gracell Biotechnologies. Gracell Biotechnologies is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kamada$129.34M1.79-$2.32M$0.0864.63
Gracell Biotechnologies$60K3,682.45-$88.08M-$1.31-2.32

Kamada currently has a consensus target price of $11.00, indicating a potential upside of 112.77%. Gracell Biotechnologies has a consensus target price of $14.20, indicating a potential upside of 367.11%. Given Gracell Biotechnologies' higher probable upside, analysts plainly believe Gracell Biotechnologies is more favorable than Kamada.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kamada
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Gracell Biotechnologies
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Kamada has a net margin of 2.35% compared to Gracell Biotechnologies' net margin of 0.00%. Kamada's return on equity of 7.42% beat Gracell Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Kamada2.35% 7.42% 4.08%
Gracell Biotechnologies N/A -45.76%-37.85%

Kamada received 279 more outperform votes than Gracell Biotechnologies when rated by MarketBeat users. Likewise, 64.88% of users gave Kamada an outperform vote while only 60.00% of users gave Gracell Biotechnologies an outperform vote.

CompanyUnderperformOutperform
KamadaOutperform Votes
303
64.88%
Underperform Votes
164
35.12%
Gracell BiotechnologiesOutperform Votes
24
60.00%
Underperform Votes
16
40.00%

In the previous week, Gracell Biotechnologies had 1 more articles in the media than Kamada. MarketBeat recorded 1 mentions for Gracell Biotechnologies and 0 mentions for Kamada. Gracell Biotechnologies' average media sentiment score of 1.59 beat Kamada's score of 0.00 indicating that Gracell Biotechnologies is being referred to more favorably in the news media.

Company Overall Sentiment
Kamada Neutral
Gracell Biotechnologies Very Positive

Kamada has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Gracell Biotechnologies has a beta of -1.38, indicating that its stock price is 238% less volatile than the S&P 500.

Summary

Kamada beats Gracell Biotechnologies on 12 of the 17 factors compared between the two stocks.


Get Kamada News Delivered to You Automatically

Sign up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KMDA vs. The Competition

Export to Excel
MetricKamadaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$231.72M$6.33B$4.61B$6.27B
Dividend YieldN/A2.75%2.58%6.52%
P/E Ratio64.637.64143.2913.69
Price / Sales1.79184.332,857.8971.53
Price / Cash204.8920.7193.03100.49
Price / Book1.323.763.754.83
Net Income-$2.32M$203.37M$121.67M$186.05M
7 Day Performance-0.19%-5.80%-2.61%-3.10%
1 Month Performance-4.96%-8.06%-2.07%-4.14%
1 Year Performance14.89%8.86%9.58%5.52%

Kamada Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRCL
Gracell Biotechnologies
1.9685 of 5 stars		$3.25
+1.9%		$14.20
+336.9%		+21.1%$236.21M$60,000.00-2.48314Positive News
SBTX
Silverback Therapeutics
0 of 5 stars		$6.61
-11.3%		N/A-15.0%$238.16MN/A-2.7383Positive News
Gap Up
High Trading Volume
ATAI
Atai Life Sciences
2.2066 of 5 stars		$1.41
flat		$12.80
+807.8%		-59.3%$234.07M$230,000.00-1.53133
VSTM
Verastem
2.1861 of 5 stars		$9.50
-4.0%		$37.50
+294.7%		-12.4%$239.88M$2.60M-2.1757
IMRX
Immuneering
1.7344 of 5 stars		$7.91
-0.3%		$20.25
+156.0%		-25.2%$231.45M$320,000.00-4.1066Positive News
AKBA
Akebia Therapeutics
2.3334 of 5 stars		$1.22
-1.6%		$3.75
+207.4%		+268.8%$229.74M$292.60M-2.35204
NVCT
Nuvectis Pharma
2.2883 of 5 stars		$14.24
-1.8%		$21.00
+47.5%		+77.1%$245.36MN/A-9.1911News Coverage
High Trading Volume
SGMT
Sagimet Biosciences
1.816 of 5 stars		$11.85
+2.5%		$43.33
+265.7%		N/A$246.86MN/A0.009Positive News
RPHM
Reneo Pharmaceuticals
1.8815 of 5 stars		$7.33
+4.6%		$30.00
+309.3%		+122.9%$247.75MN/A-3.1351Positive News
LFCR
Lifecore Biomedical
1.5723 of 5 stars		$8.24
+1.0%		$9.50
+15.3%		N/A$249.84M$103.27M-2.46689News Coverage
Positive News

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:KMDA) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -